Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective
about
Pregabalin: a review of its use in adults with generalized anxiety disorder.Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitorsPregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal.Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.The cost effectiveness of pharmacological treatments for generalized anxiety disorder.The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin.Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective.Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder.Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use.Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.
P2860
Q34434641-9899C06B-CEB8-4A16-B295-A14C81872751Q35021417-0A3E3191-EFB3-44FB-878C-139F77F05AFFQ36062003-B77F72F5-3C77-42AF-AEF1-0FF9BE925C56Q36797810-AE644C07-30E2-4E01-A0C6-8E67D8FBB6FCQ37330372-7A4F4BDC-7AA2-4906-916E-B05D8DA14F43Q38091323-C7E4B002-0FC9-4D1B-8C2E-4DAB525E0E3FQ38167693-3F9C19A7-7585-45C5-A759-441A3271A4A8Q38168858-0499086F-0DD7-4C50-86D5-325717EC5FA1Q38175904-6BEF5657-32CE-4CAF-8C1B-C1DF274606C4Q39079619-3AE803E3-D415-4F57-8D32-E0249E9DD486Q42606471-808E0B89-E963-412A-A47D-6CFC3FB0EF05Q53091817-BD3714D5-2CBD-4088-83A0-82DA6403D772
P2860
Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cost-effectiveness of pregabal ...... ngs from a Spanish perspective
@ast
Cost-effectiveness of pregabal ...... ngs from a Spanish perspective
@en
type
label
Cost-effectiveness of pregabal ...... ngs from a Spanish perspective
@ast
Cost-effectiveness of pregabal ...... ngs from a Spanish perspective
@en
prefLabel
Cost-effectiveness of pregabal ...... ngs from a Spanish perspective
@ast
Cost-effectiveness of pregabal ...... ngs from a Spanish perspective
@en
P2093
P2860
P1476
Cost-effectiveness of pregabal ...... ngs from a Spanish perspective
@en
P2093
Ellen Dukes
Gerry Oster
Javier Rejas
Marko Mychaskiw
Montserrat Vera-Llonch
Oleg Sofrygin
P2860
P2888
P356
10.1007/S10198-009-0160-7
P577
2009-06-09T00:00:00Z